Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

NCT02132624 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.

NCT NCT02132624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02132624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Lead sponsor
Uppsala University
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2014
Completion date
May 31, 2017
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell leukemia, b cell lymphoma